References: Influenza

  • Adams K, Tastad KJ, Huang S, Ujamaa D, Kniss K, Cummings C, et al. Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza - United States, 2021-22 Influenza Season. MMWR Morb Mortal Wkly Rep 2022;71(50):1589-96. https://www.ncbi.nlm.nih.gov/pubmed/36520656
  • Adlhoch C, Delgado-Sanz C, Carnahan A, Larrauri A, Popovici O, Bossuyt N, et al. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020. Euro Surveill 2023;28(4). https://www.ncbi.nlm.nih.gov/pubmed/36700868
  • Center for Disease Control (CDC). About Influenza Antiviral Medications. Influenza. Atlanta, GA: Center for Disease Control (CDC),. 2022; Updated September 1 2022. Accessed 27 November. https://www.cdc.gov/flu/hcp/antivirals/index.html
  • Chow EJ, Beigi RH, Riley LE, Uyeki TM. Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy. Open Forum Infect Dis 2021;8(6):ofab138. https://www.ncbi.nlm.nih.gov/pubmed/34189160
  • Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet 2015;385(9979):1729-37. https://www.ncbi.nlm.nih.gov/pubmed/25640810
  • Fang YH, Hsu TH, Lin TY, Liu CH, Chou SC, Wu JY, et al. Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;19(8):1039-46. https://www.ncbi.nlm.nih.gov/pubmed/33641583
  • Gao Y, Guyatt G, Uyeki TM, Liu M, Chen Y, Zhao Y, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2024;404(10454):753-63. https://www.ncbi.nlm.nih.gov/pubmed/39181595
  • Gao Y, Zhao Y, Liu M, Luo S, Chen Y, Chen X, et al. Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis. JAMA Intern Med 2025. https://www.ncbi.nlm.nih.gov/pubmed/39804622
  • Hanula RBB-C, Emilie, NClin; Mendel, Arielle, MD, MSc; Ward, Brian J. MSc, MDCM; Lee, Todd C. MD, MPH; McDonald, Emily G. MD, MSc. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza. JAMA Internal Medicine JAMA Internal Medicine; 2023. 184 Accessed 17/09/24. jamainternal_hanula_2023_oi_230015_1703712306.14243.pdf
  • Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018;379(10):913-23. https://www.ncbi.nlm.nih.gov/pubmed/30184455
  • Health Protection Agency (HPA). Paediatric management of critically ill children with pandemic (H1N1) 2009 Influenza. Public Health England, editor. Kew, Richmond: Department of Health,; 2011. p. 9. https://www.gov.uk/government/publications/h1n1-flu-critical-care-management
  • Health Protection Agency (HPA). Seasonal influenza: managing cases in critical care units. Public Health England, editor. 2.0 ed. London: Department of Health,; 2019. p. 35. https://www.gov.uk/government/publications/seasonal-influenza-managing-cases-in-critical-care-units
  • Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess 2016;20(42):1-242. https://www.ncbi.nlm.nih.gov/pubmed/27246259
  • Hernu R, Chroboczek T, Madelaine T, Casalegno JS, Lina B, Cour M, et al. Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis. Intensive Care Med 2018;44(2):257-60. https://pubmed.ncbi.nlm.nih.gov/29026934/
  • Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012;156(7):512-24. https://pubmed.ncbi.nlm.nih.gov/22371849/
  • Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 2020;383(4):309-20. https://www.ncbi.nlm.nih.gov/pubmed/32640124
  • Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020;20(10):1204-14. https://www.ncbi.nlm.nih.gov/pubmed/32526195
  • Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545. https://www.ncbi.nlm.nih.gov/pubmed/24811411
  • Katzen J, Kohn R, Houk JL, Ison MG. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes. Clin Infect Dis 2019;69(1):52-8. https://www.ncbi.nlm.nih.gov/pubmed/30304487
  • Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016;10(5):394-403. https://www.ncbi.nlm.nih.gov/pubmed/27232677
  • Kumar D, Ison MG, Mira JP, Welte T, Hwan Ha J, Hui DS, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis 2022;22(5):718-30. https://www.ncbi.nlm.nih.gov/pubmed/35085510
  • Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, et al. Antiviral Approaches against Influenza Virus. Clin Microbiol Rev 2023;36(1):e0004022. https://www.ncbi.nlm.nih.gov/pubmed/36645300
  • Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the Uncertainties of COVID-19-Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis. J Infect Dis 2021;224(10):1631-40. https://www.ncbi.nlm.nih.gov/pubmed/33770176
  • Li-Kim-Moy J, Yin JK, Patel C, Beard FH, Chiu C, Macartney KK, et al. Australian vaccine preventable disease epidemiological review series: Influenza 2006 to 2015. Commun Dis Intell Q Rep 2016;40(4):E482-E95. https://www.ncbi.nlm.nih.gov/pubmed/28043223
  • Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis 2018;66(10):1492-500. https://www.ncbi.nlm.nih.gov/pubmed/29186364
  • Marty FM, Vidal-Puigserver J, Clark C, Gupta SK, Merino E, Garot D, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 2017;5(2):135-46. https://www.ncbi.nlm.nih.gov/pubmed/28094141
  • Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One 2013;8(4):e60348. https://pubmed.ncbi.nlm.nih.gov/23565231/
  • Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2(5):395-404. https://www.ncbi.nlm.nih.gov/pubmed/24815805
  • Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, et al. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother 2013;57(8):3478-87. https://www.ncbi.nlm.nih.gov/pubmed/23669386
  • Sarda C, Palma P, Rello J. Severe influenza: overview in critically ill patients. Curr Opin Crit Care 2019;25(5):449-57. https://www.ncbi.nlm.nih.gov/pubmed/31313681
  • Scott LJ. Peramivir: A Review in Uncomplicated Influenza. Drugs 2018;78(13):1363-70. https://www.ncbi.nlm.nih.gov/pubmed/30196350
  • Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. Int J Epidemiol 2021;50(4):1124-33. https://www.ncbi.nlm.nih.gov/pubmed/33942104
  • Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet 2022;399(10334):1463-4. https://www.ncbi.nlm.nih.gov/pubmed/35344735
  • Uyeki TM. A Step Forward in the Treatment of Influenza. N Engl J Med 2018;379(10):975-7. https://www.ncbi.nlm.nih.gov/pubmed/30184452
  • Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, et al. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. J Infect Dis 2020;221(3):356-66. https://www.ncbi.nlm.nih.gov/pubmed/31314899
  • Verweij PE, Rijnders BJA, Bruggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 2020;46(8):1524-35. https://www.ncbi.nlm.nih.gov/pubmed/32572532
  • Walsh PS, Schnadower D, Zhang Y, Ramgopal S, Shah SS, Wilson PM. Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020. JAMA Pediatr 2022;176(11):e223261. https://www.ncbi.nlm.nih.gov/pubmed/36121673
  • World Health Organization (WHO). Clinical Practice Guidelines for Influenza. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240097759
  • Xu M, Cai T, Yue T, Zhang P, Huang J, Liu Q, et al. Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0-5 years) with influenza infection. Int J Infect Dis 2023;128:157-65. https://www.ncbi.nlm.nih.gov/pubmed/36608788